Thermo Fisher Scientific stock review highlights drug-development expansion
Published on 10/10/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Thermo Fisher presented expanded drug-development capabilities at CPHI Milan.
- Generative AI reduced informed-consent drafting time by 50 percent.
- Third-quarter results are scheduled for October 21, 2026.
Market context: Market report S&P 500.
Thermo Fisher Scientific presented expanded drug-development, manufacturing and clinical capabilities at CPHI Milan from October 6 through October 8, 2026, according to a Business Wire release.
The week in figures
The release said generative artificial intelligence reduced master informed-consent-form drafting time by 50 percent in aggregate. It also reported reductions of 15 percent to 30 percent in some clinical research activities.
Chronology of the week
On October 6, 2026, Thermo Fisher highlighted OSD Express and Steriles Express Solutions, expanded manufacturing capacity and digital tools at CPHI Milan. The company said Steriles Express Early Development is designed to provide Phase I or II clinical-trial material in as little as 20 weeks, while Steriles Express Tech Transfer can provide a Phase III good-manufacturing-practice batch in as little as 26 weeks, subject to program parameters and scope. These details were provided by Business Wire.
Dates of the coming week
Thermo Fisher Scientific said in an investor-relations announcement dated September 28, 2026, that it will release third-quarter 2026 results before the market opens on October 21, 2026, and hold a conference call at 7:00 a.m. Eastern Time. The company will discuss its financial performance and future expectations, according to Thermo Fisher Scientific Investor Relations.
